Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹16,470 Cr
Revenue (TTM)
₹1,477 Cr
Net Profit (TTM)
₹260 Cr
ROE
26.4 %
ROCE
33.5 %
P/E Ratio
63.3
P/B Ratio
10.8
Industry P/E
38.08
EV/EBITDA
47.6
Div. Yield
0.1 %
Debt to Equity
0.1
Book Value
₹1187.8
EPS
₹156
Face value
10
Shares outstanding
12,829,889
CFO
₹983.33 Cr
EBITDA
₹1,487.96 Cr
Net Profit
₹742.64 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neuland Lab
| -6.5 | 8.2 | 15.9 | 97.8 | 129.9 | 99.2 | 43.4 |
|
BSE Healthcare
| -2.2 | 3.8 | 12.4 | 18.4 | 26.7 | 22.3 | 11.0 |
|
BSE Mid Cap
| -0.6 | 3.3 | 18.0 | 0.1 | 28.1 | 29.9 | 16.4 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Neuland Lab
| 159.8 | 217.4 | 7.9 | 41.7 | 161.5 | -12.2 | -48.2 |
|
BSE Mid Cap
| 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 | -13.3 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Neuland Lab
|
12,832.0 | 16,469.5 | 1,476.8 | 260.1 | 17.5 | 13.7 | 63.3 | 10.8 |
| 462.2 | 4,219.0 | 2,387.0 | 168.1 | 9.7 | 12.7 | 25.1 | 3.1 | |
| 1,018.0 | 12,494.1 | 2,386.9 | 485.6 | 26.1 | 18.1 | 25.7 | 4.4 | |
| 938.6 | 16,278.9 | 1,030.0 | 305.2 | 34.9 | 29.7 | 53.3 | 14.4 | |
| 2,095.8 | 21,910.8 | 1,200.1 | 373.0 | 37.7 | 21.8 | 59 | 12.1 | |
| 6,687.5 | 1,77,571.9 | 9,360.0 | 2,191.0 | 27.4 | 15.3 | 81 | 11.9 | |
| 1,333.8 | 25,263.4 | 7,896.0 | 707.5 | 13.8 | 16.1 | 37.1 | 5.7 | |
| 2,399.3 | 3,976.4 | 653.4 | 183.2 | 21.2 | 20.9 | 21.7 | 7.5 | |
| 248.5 | 5,429.0 | 6.7 | -160.8 | -2,578.1 | -106.2 | -- | 49.4 | |
| 601.7 | 4,230.0 | 2,028.9 | 150.6 | 7.5 | 6.2 | 30.8 | 1.7 |
1 min read•By Research Desk
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics,... cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Read more
Incorporated
1984
Chairman
Davuluri Rama Mohan Rao
Managing Director
Davuluri Saharsh Rao
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Neuland Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Neuland Laboratories Ltd stood at ₹ 2,180 Cr as on 31-Mar-25
The share price of Neuland Laboratories Ltd is ₹12,832.00 (NSE) and ₹12,836.85 (BSE) as of 16-Jun-2025 IST. Neuland Laboratories Ltd has given a return of 129.91% in the last 3 years.
Neuland Laboratories Ltd has a market capitalisation of ₹ 16,470 Cr as on 16-Jun-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Neuland Laboratories Ltd is 10.81 times as on 16-Jun-2025, a 230% premium to its peers’ median range of 3.28 times.
The P/E ratio of Neuland Laboratories Ltd is 63.32 times as on 16-Jun-2025, a 66% premium to its peers’ median range of 38.08 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Neuland Laboratories Ltd and enter the required number of quantities and click on buy to purchase the shares of Neuland Laboratories Ltd.
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
The promoters of Neuland Laboratories Ltd are Davuluri Ownership Trust and DAVULURI SUCHETH RAO. They collectively own 27.99 per cent of the total equity. The chairman of the company is Davuluri Rama Mohan Rao
There is no promoter pledging in Neuland Laboratories Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
25,824
|
|
|
22,080
|
|
|
16,554
|
|
|
12,424
|
|
|
1,77,076
|
|
|
5,139
|
|
|
4,280
|
|
|
4,235
|
|
|
3,869
|
| Neuland Laboratories Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
13.71
|
|
Operating margin(%)
|
17.45
|
|
Net Margin(%)
|
17.37
|
|
Dividend yield(%)
|
0.09
|
Yes, TTM profit after tax of Neuland Laboratories Ltd was ₹260 Cr.
₹-361.00
(
